Evaluate the most promising epigenetic pathways and reveal tactics to discover small molecule inhibitors for second generation pathways including bromodomains, demethylases and histone methyltransferase substrates
- Nessa Carey, Pfizer, UK highlights the opportunities and challenges industry is facing on the identification, validation, druggability and disease applications of emerging epigenetic targets
- The Institute of Cancer Research, EpiTherapeutics, University of Oxford, and Epizyme, provide case study insights on efforts to understand biological functions and uncover strategies to discover small molecule inhibitors of emerging epigenetic pathways including Bromodomains, Demethylases and Histone Methyltransferases
- SGC Oxford reveal how open innovation is driving chemical probe detection
- Explore how Acetylon Pharmaceuticals and Mirna Therapeutics, Inc. are translating knowledge of epigenetic pathways into effective drugs
Free Registration: If you’re willing to produce a conference summary for this meeting, we’ll provide you free registration. Contact us if you’re interested.
* This offer is available to the first qualified respondent.